NCT00400309View on ClinicalTrials.gov

Safety of REPEVAX® Given One Month After REVAXIS®

PHASE3CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions

Healthy Adult

Interventions

BIOLOGICAL

REPEVAX® after REVAXIS®

Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)

BIOLOGICAL

REPEVAX® after Placebo

Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo

Trial Locations (4)

Unknown

Clermont-Ferrand

Lyon

Montpellier

Paris

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00400309 - Safety of REPEVAX® Given One Month After REVAXIS® | Biotech Hunter | Biotech Hunter